[99m-Technetium-mercaptoacetyltriglycine (MAG3) for the demonstration of the kidney changes following extracorporeal shockwave lithotripsy. A prospective study of 117 patients].
Extracorporeal shock wave lithotripsy (ESWL) has become the treatment of choice for urinary calculi. 117 patients were studied prospectively with 99mTc mercaptoacetyltriglycine (MAG3) before and after ESWL. 79 (66%) of the 119 kidneys treated had abnormal findings. Of these 63/119 (53%) had abnormal scans. 41 (65%) had focal lesions with a delayed intrarenal transport. The remaining 22 had a diffuse delay of intrarenal transport. A loss of relative renal function of 3% and more compared to the pretreatment values was observed in 50/119 (42%) patients. 99mTc MAG3 should be done routinely together with radiologic tests (CT or MRI) before and after ESWL to select the patients at risk for post ESWL hypertension.
Schaub
T
T
Klinik mit Poliklinik für Radiologie, Johannes-Gutenberg-Universität, Mainz.
Witsch
U
U
el-Damanhoury
H
H
Nägele-Wöhrle
B
B
Hahn
K
K
D005260:Female; D015902:Gamma Cameras; D006801:Humans; D007668:Kidney / Q000000981:diagnostic imaging* / Q000503:physiopathology; D007669:Kidney Calculi / Q000150:complications / Q000000981:diagnostic imaging / Q000628:therapy; D007674:Kidney Diseases / Q000000981:diagnostic imaging* / Q000453:epidemiology / Q000209:etiology; D008096:Lithotripsy / Q000009:adverse effects / Q000706:statistics & numerical data; D008297:Male; D011446:Prospective Studies; D011877:Radionuclide Imaging; D017263:Technetium Tc 99m Mertiatide; D013997:Time Factors
D017263:Technetium Tc 99m Mertiatide